Antidepressants and suicide: a commentary on a significant contribution to this debate.
Goldney
Robert D
RD
University of Adelaide, Australia. robert.goldney@adelaide.edu.au
D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003863:Depression / Q000188:drug therapy*; D004308:Dothiepin / Q000627:therapeutic use; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000627:therapeutic use; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013405:Suicide / Q000706:statistics & numerical data*; D013406:Suicide, Attempted / Q000706:statistics & numerical data*; D013997:Time Factors; D006113:United Kingdom
D018759:Adrenergic Uptake Inhibitors; D000639:Amitriptyline; D000929:Antidepressive Agents, Tricyclic; D004308:Dothiepin; D005473:Fluoxetine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors